| 34.71 2.71 (8.47%) | 08-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 42.02 | 1-year : | 49.08 |
| Resists | First : | 35.97 | Second : | 42.02 |
| Pivot price | 29.69 |
|||
| Supports | First : | 28.03 | Second : | 23.11 |
| MAs | MA(5) : | 32.98 |
MA(20) : | 29.34 |
| MA(100) : | 25.35 |
MA(250) : | 18.36 |
|
| MACD | MACD : | 1.8 |
Signal : | 1.3 |
| %K %D | K(14,3) : | 76.3 |
D(3) : | 74.4  |
| RSI | RSI(14): 67 |
|||
| 52-week | High : | 37.9 | Low : | 7.44 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ FTH ] has closed below upper band by 13.5%. Bollinger Bands are 21.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 35.07 - 35.24 | 35.24 - 35.42 |
| Low: | 29.94 - 30.1 | 30.1 - 30.26 |
| Close: | 34.42 - 34.71 | 34.71 - 34.99 |
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway.
Mon, 24 Aug 2026
Wall Street Analysts Predict a 72.22% Upside in Faeth Therapeutics, Inc. (FTH): Here's What You Should Know - Yahoo Finance
Sun, 23 Aug 2026
FTH Technical Analysis & ETF Price Forecast - Intellectia AI
Fri, 21 Aug 2026
Faeth Therapeutics Market Sentiment - Benzinga France
Sun, 16 Aug 2026
FTH: Faeth Therapeutics, Inc. - Insider Transations - Zacks Investment Research
Fri, 14 Aug 2026
Faeth Therapeutics (FTH) investor group reports 0% ownership in amended 13G - Stock Titan
Fri, 14 Aug 2026
Faeth Therapeutics (FTH) investor Caligan reports 2.4% stake in 13G/A - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 26 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 64.4 (%) |
| Shares Short | 816 (K) |
| Shares Short P.Month | 780 (K) |
| EPS | -60.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.69 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.8 % |
| Return on Equity (ttm) | -195.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -34 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -0.58 |
| PEG Ratio | 0 |
| Price to Book value | 5.18 |
| Price to Sales | 0 |
| Price to Cash Flow | -26.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|